Anokion
Ecublens
About Anokion
Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $112.6M
- Funding stage: M&A
- Last round: Series Unknown (Oct 2022)
- Website: anokion.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Clinical Trials, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/anokion-70795 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.